We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Zoetis (ZTS) Stock Moves -1.16%: What You Should Know
Read MoreHide Full Article
The latest trading session saw Zoetis (ZTS - Free Report) ending at $163.11, denoting a -1.16% adjustment from its last day's close. The stock outperformed the S&P 500, which registered a daily loss of 1.97%. Elsewhere, the Dow lost 1.69%, while the tech-heavy Nasdaq lost 2.7%.
Heading into today, shares of the animal health company had gained 0.02% over the past month, outpacing the Medical sector's loss of 2.45% and the S&P 500's loss of 2.79% in that time.
The upcoming earnings release of Zoetis will be of great interest to investors. The company's earnings report is expected on May 6, 2025. The company's earnings per share (EPS) are projected to be $1.41, reflecting a 2.17% increase from the same quarter last year. Simultaneously, our latest consensus estimate expects the revenue to be $2.19 billion, showing a 0.12% escalation compared to the year-ago quarter.
For the full year, the Zacks Consensus Estimates project earnings of $6.08 per share and a revenue of $9.31 billion, demonstrating changes of +2.7% and +0.59%, respectively, from the preceding year.
It is also important to note the recent changes to analyst estimates for Zoetis. Such recent modifications usually signify the changing landscape of near-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the company's business operations and its ability to generate profits.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 0.17% higher. Zoetis currently has a Zacks Rank of #4 (Sell).
From a valuation perspective, Zoetis is currently exchanging hands at a Forward P/E ratio of 27.15. This represents a premium compared to its industry's average Forward P/E of 15.51.
It's also important to note that ZTS currently trades at a PEG ratio of 2.91. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. As the market closed yesterday, the Medical - Drugs industry was having an average PEG ratio of 1.06.
The Medical - Drugs industry is part of the Medical sector. With its current Zacks Industry Rank of 77, this industry ranks in the top 31% of all industries, numbering over 250.
The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Zoetis (ZTS) Stock Moves -1.16%: What You Should Know
The latest trading session saw Zoetis (ZTS - Free Report) ending at $163.11, denoting a -1.16% adjustment from its last day's close. The stock outperformed the S&P 500, which registered a daily loss of 1.97%. Elsewhere, the Dow lost 1.69%, while the tech-heavy Nasdaq lost 2.7%.
Heading into today, shares of the animal health company had gained 0.02% over the past month, outpacing the Medical sector's loss of 2.45% and the S&P 500's loss of 2.79% in that time.
The upcoming earnings release of Zoetis will be of great interest to investors. The company's earnings report is expected on May 6, 2025. The company's earnings per share (EPS) are projected to be $1.41, reflecting a 2.17% increase from the same quarter last year. Simultaneously, our latest consensus estimate expects the revenue to be $2.19 billion, showing a 0.12% escalation compared to the year-ago quarter.
For the full year, the Zacks Consensus Estimates project earnings of $6.08 per share and a revenue of $9.31 billion, demonstrating changes of +2.7% and +0.59%, respectively, from the preceding year.
It is also important to note the recent changes to analyst estimates for Zoetis. Such recent modifications usually signify the changing landscape of near-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the company's business operations and its ability to generate profits.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 0.17% higher. Zoetis currently has a Zacks Rank of #4 (Sell).
From a valuation perspective, Zoetis is currently exchanging hands at a Forward P/E ratio of 27.15. This represents a premium compared to its industry's average Forward P/E of 15.51.
It's also important to note that ZTS currently trades at a PEG ratio of 2.91. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. As the market closed yesterday, the Medical - Drugs industry was having an average PEG ratio of 1.06.
The Medical - Drugs industry is part of the Medical sector. With its current Zacks Industry Rank of 77, this industry ranks in the top 31% of all industries, numbering over 250.
The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.